

# BC Cancer Protocol Summary for Treatment of Advanced Granulosa Cell Carcinoma using Leuprolide Acetate

|                          |                     |
|--------------------------|---------------------|
| <b>Protocol Code</b>     | GOGCLEU             |
| <b>Tumour Group</b>      | Gynecology          |
| <b>Contact Physician</b> | GO Systemic Therapy |

## ELIGIBILITY:

Patients must have:

- Metastatic granulosa cell carcinoma of the ovary that is no longer amenable to surgical resection,
- At least one prior line of therapy (chemotherapy or endocrine therapy)

## TESTS:

- Bone density study before or after 2-3 months of therapy
- Bone density every 2-3 years
- If clinically indicated at baseline and throughout treatment: CBC & Diff, creatinine, total bilirubin, ALT, LH, FSH, estradiol, cholesterol, triglycerides

## TREATMENT:

| Drug                              | Dose and BC Cancer Administration Guideline  |
|-----------------------------------|--|
| leuprolide acetate (LUPRON DEPOT) | <ul style="list-style-type: none"><li>▪ 7.5 mg IM every month, <b>or</b></li><li>▪ 22.5 mg IM every 3 months, <b>or</b></li><li>▪ 30 mg IM every 4 months, <b>or</b></li></ul>   |
| OR                                |  |
| leuprolide acetate (ELIGARD)      | <ul style="list-style-type: none"><li>▪ 7.5 mg subcutaneous every month, <b>or</b></li><li>▪ 22.5 mg subcutaneous every 3 months, <b>or</b></li><li>▪ 30 mg subcutaneous every 4 months, <b>or</b></li><li>▪ 45 mg subcutaneous every 6 months</li></ul> |

Where clinically appropriate, consider the subcutaneous route as it is associated with less injection-related discomfort.

Continue treatment until disease progression on intolerable toxicity.

## PRECAUTIONS:

1. **Injection site reactions:** Injectable LHRH agonist may cause irritation of the injection site.
2. **Osteoporosis:** Androgen deprivation therapy may cause an increased risk of osteoporosis and fractures. Physicians should assess osteoporosis risk and manage as per clinical practice guidelines.
3. **Vaginal bleeding, or breakthrough bleeding,** may occur during early leuprolide therapy in patients with an intact uterus.

**Contact the GO Systemic Therapy physician at your regional cancer centre or the GO Systemic Therapy Chair with any problems or questions regarding this treatment program**

**References**

1. Foster KI, Flores Legarreta A, Kamat et al. Clinical Outcomes of Leuprolide Acetate in the Treatment of Recurrent Ovarian Granulosa Cell Tumors. *Am J Obstet Gynecol.* June 2023; 228(6): 724.e1–724.e9.